Welcome to our dedicated page for Revive Therapeutics news (Ticker: RVVTF), a resource for investors and traders seeking the latest updates and insights on Revive Therapeutics stock.
Revive Therapeutics Ltd. develops specialty life sciences programs focused on infectious diseases and medical countermeasures. Company news commonly centers on Bucillamine, including intellectual-property filings, granted patent coverage, and research updates on its potential use in infectious diseases and nerve-agent exposure.
Revive updates also cover work with Defence R&D Canada – Suffield Research Centre, botanical research compounds, molecular hydrogen therapeutic programs, and financing activity. Capital-structure news includes private placements, debt settlement, unit issuances, common share purchase warrants, compensation options, and the use of proceeds for working capital and trade payables.
Revive Therapeutics Ltd. (OTCQB: RVVTF) announced its inclusion in the inaugural launch of AdvisorShares Psychedelics ETF (PSIL), which began trading on September 16, 2021. This ETF focuses on the emerging psychedelics sector, featuring 16 companies involved in biotechnology and life sciences. CEO Michael Frank expressed that this inclusion validates Revive's strategy regarding psilocybin therapies for mental health. Revive is also advancing psilocybin-based therapeutics and is exploring Bucillamine for treating infectious diseases, including COVID-19.
Revive Therapeutics Ltd. (OTCQB: RVVTF) has entered into an exclusive licensing agreement with Puerto Rico Science Technology and Research Trust, encompassing research from Universidad Central del Caribe and St. Jude Children’s Research Hospital. This collaboration focuses on the medicinal mushroom Ganoderma lucidum, recognized for its anticancer properties, especially against aggressive breast cancers. Revive aims to advance towards FDA clinical trials, following successful in vitro studies and the discovery of key compounds like ergosterol peroxide, which shows significant anticancer activity.
Revive Therapeutics Ltd. (CSE: RVV, USA: RVVTF) has announced its common shares will begin trading on the OTCQB Market from June 28, 2021. This U.S. listing aims to enhance awareness and investor reach. CEO Michael Frank emphasized the company's pursuit of FDA EUA approval for Bucillamine in treating COVID-19 and the advancement of psychedelics for mental health therapies. Revive is also focused on cannabinoid therapies for rare inflammatory diseases, alongside its acquisitions and regulatory incentives from the FDA.